Adult Dose Autoinjector Device Manufacturing

The contract entails the full-scale manufacturing of 1.5 million adult-dose autoinjector devices under firm-fixed-price terms, with strict requirements for temperature-controlled production processes and comprehensive stability assurance throughout the lifecycle of the devices. The work must be performed to ensure product integrity and regulatory compliance, with all phases of manufacturing conducted under controlled environmental conditions to maintain clinical efficacy and safety standards. The production timeline is tied to a firm deadline, with responses due by July 30, 2026, following the solicitation’s public posting on July 2, 2026. This subcontract falls under NAICS code 325412, indicating pharmaceutical and medicinal product manufacturing, and is managed by the Department of Health and Human Services through Barda - ASPR / DAAPPO / Barda DCMA. The place of performance is designated as Washington, D.C., with a zip code of 20024, suggesting that key logistical, oversight, or final assembly activities must occur in or near the federal capital. No set-aside provisions are specified, and the contract is intended for full competition among qualified manufacturers capable of meeting rigorous quality, volume, and environmental standards required for high-volume pharmaceutical device production.